HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Cocrystal Pharma (NASDAQ:COCP) but lowers the price target from $35 to $12.
May 24, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cocrystal Pharma's price target has been lowered from $35 to $12 by HC Wainwright & Co., but the Buy rating is maintained.
The lowered price target may cause some short-term uncertainty among investors, but the maintained Buy rating indicates that the analyst still believes in the company's potential. The impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100